Production tech tie-up boosts ProMetic's Chinese business
This article was originally published in Scrip
The Canadian company ProMetic Life Sciences has taken another major step into the Chinese market through an order from a leading but undisclosed biopharma company in the country for technology to be used in the large-scale manufacture of a biosimilar product. ProMetic will supply its proprietary Mimetic Ligand affinity adsorbent, which is used to purify and eliminate pathogens from biologics during commercial manufacture.
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.